Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation. / De Backer, Ole; Pilgrim, Thomas; Simonato, Matheus; Mackensen, G Burkhard; Fiorina, Claudia; Veulemanns, Verena; Cerillo, Alfredo; Schofer, Joachim; Amabile, Nicolas; Achkouty, Guy; Schäfer, Ulrich; Deutsch, Marcus-André; Sinning, Jan-Malte; Rahman, Mohammed S; Sawaya, Fadi J; Hildick-Smith, David; Hernandez, Jose Maria; Kim, Won-Keun; Lefevre, Thierry; Seiffert, Moritz; Bleiziffer, Sabine; Petronio, Anna Sonia; Van Mieghem, Nicolas; Taramasso, Maurizio; Søndergaard, Lars; Windecker, Stephan; Latib, Azeem; Dvir, Danny.

I: The American Journal of Cardiology, Bind 122, Nr. 6, 2018, s. 1028-1035.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

De Backer, O, Pilgrim, T, Simonato, M, Mackensen, GB, Fiorina, C, Veulemanns, V, Cerillo, A, Schofer, J, Amabile, N, Achkouty, G, Schäfer, U, Deutsch, M-A, Sinning, J-M, Rahman, MS, Sawaya, FJ, Hildick-Smith, D, Hernandez, JM, Kim, W-K, Lefevre, T, Seiffert, M, Bleiziffer, S, Petronio, AS, Van Mieghem, N, Taramasso, M, Søndergaard, L, Windecker, S, Latib, A & Dvir, D 2018, 'Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation', The American Journal of Cardiology, bind 122, nr. 6, s. 1028-1035. https://doi.org/10.1016/j.amjcard.2018.05.044

APA

De Backer, O., Pilgrim, T., Simonato, M., Mackensen, G. B., Fiorina, C., Veulemanns, V., Cerillo, A., Schofer, J., Amabile, N., Achkouty, G., Schäfer, U., Deutsch, M-A., Sinning, J-M., Rahman, M. S., Sawaya, F. J., Hildick-Smith, D., Hernandez, J. M., Kim, W-K., Lefevre, T., ... Dvir, D. (2018). Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation. The American Journal of Cardiology, 122(6), 1028-1035. https://doi.org/10.1016/j.amjcard.2018.05.044

Vancouver

De Backer O, Pilgrim T, Simonato M, Mackensen GB, Fiorina C, Veulemanns V o.a. Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation. The American Journal of Cardiology. 2018;122(6):1028-1035. https://doi.org/10.1016/j.amjcard.2018.05.044

Author

De Backer, Ole ; Pilgrim, Thomas ; Simonato, Matheus ; Mackensen, G Burkhard ; Fiorina, Claudia ; Veulemanns, Verena ; Cerillo, Alfredo ; Schofer, Joachim ; Amabile, Nicolas ; Achkouty, Guy ; Schäfer, Ulrich ; Deutsch, Marcus-André ; Sinning, Jan-Malte ; Rahman, Mohammed S ; Sawaya, Fadi J ; Hildick-Smith, David ; Hernandez, Jose Maria ; Kim, Won-Keun ; Lefevre, Thierry ; Seiffert, Moritz ; Bleiziffer, Sabine ; Petronio, Anna Sonia ; Van Mieghem, Nicolas ; Taramasso, Maurizio ; Søndergaard, Lars ; Windecker, Stephan ; Latib, Azeem ; Dvir, Danny. / Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation. I: The American Journal of Cardiology. 2018 ; Bind 122, Nr. 6. s. 1028-1035.

Bibtex

@article{6d5b36a001464c39b66a0d2969d34b6b,

title = "Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation",

abstract = "Patients with pure native aortic valve regurgitation (NAVR) and increased surgical risk are often denied surgery. This retrospective study aimed to evaluate the {"}off-label{"} use of transcatheter heart valves (THV) for the treatment of NAVR. A total of 254 high surgical risk patients with NAVR (age 74 ± 12 years, Society of Thoracic Surgeons risk score 6.6 ± 6.2%) underwent transcatheter aortic valve implantation (TAVI) with early generation (43%) or newer generation (57%) devices at 46 different sites. Device success was significantly higher in patients treated with newer as compared with early generation THV (82% vs 47%, p <0.001). The difference was driven by lower rates of device malpositioning (9% vs 33%) and aortic regurgitation (AR) ≥ moderate (4% vs 31%) and translated into higher clinical efficacy at 30 days in patients treated with newer as compared with early generation THV (72% vs 56%, p = 0.041). Both THV under- and oversizing were associated with an increased risk of THV malpositioning. In conclusion, TAVI is a feasible treatment strategy in selected high-risk patients with NAVR but is associated with a considerable risk of THV malpositioning and residual AR. Although newer-generation THV are associated with better outcomes, novel devices for the treatment of NAVR are warranted.",

author = "{De Backer}, Ole and Thomas Pilgrim and Matheus Simonato and Mackensen, {G Burkhard} and Claudia Fiorina and Verena Veulemanns and Alfredo Cerillo and Joachim Schofer and Nicolas Amabile and Guy Achkouty and Ulrich Sch{\"a}fer and Marcus-Andr{\'e} Deutsch and Jan-Malte Sinning and Rahman, {Mohammed S} and Sawaya, {Fadi J} and David Hildick-Smith and Hernandez, {Jose Maria} and Won-Keun Kim and Thierry Lefevre and Moritz Seiffert and Sabine Bleiziffer and Petronio, {Anna Sonia} and {Van Mieghem}, Nicolas and Maurizio Taramasso and Lars S{\o}ndergaard and Stephan Windecker and Azeem Latib and Danny Dvir",

note = "Copyright {\textcopyright} 2018. Published by Elsevier Inc.",

year = "2018",

doi = "10.1016/j.amjcard.2018.05.044",

language = "English",

volume = "122",

pages = "1028--1035",

journal = "Am. J. Cardiol.",

issn = "0002-9149",

publisher = "Elsevier",

number = "6",

}

RIS

TY - JOUR

T1 - Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation

AU - De Backer, Ole

AU - Pilgrim, Thomas

AU - Simonato, Matheus

AU - Mackensen, G Burkhard

AU - Fiorina, Claudia

AU - Veulemanns, Verena

AU - Cerillo, Alfredo

AU - Schofer, Joachim

AU - Amabile, Nicolas

AU - Achkouty, Guy

AU - Schäfer, Ulrich

AU - Deutsch, Marcus-André

AU - Sinning, Jan-Malte

AU - Rahman, Mohammed S

AU - Sawaya, Fadi J

AU - Hildick-Smith, David

AU - Hernandez, Jose Maria

AU - Kim, Won-Keun

AU - Lefevre, Thierry

AU - Seiffert, Moritz

AU - Bleiziffer, Sabine

AU - Petronio, Anna Sonia

AU - Van Mieghem, Nicolas

AU - Taramasso, Maurizio

AU - Søndergaard, Lars

AU - Windecker, Stephan

AU - Latib, Azeem

AU - Dvir, Danny

PY - 2018

Y1 - 2018

N2 - Patients with pure native aortic valve regurgitation (NAVR) and increased surgical risk are often denied surgery. This retrospective study aimed to evaluate the "off-label" use of transcatheter heart valves (THV) for the treatment of NAVR. A total of 254 high surgical risk patients with NAVR (age 74 ± 12 years, Society of Thoracic Surgeons risk score 6.6 ± 6.2%) underwent transcatheter aortic valve implantation (TAVI) with early generation (43%) or newer generation (57%) devices at 46 different sites. Device success was significantly higher in patients treated with newer as compared with early generation THV (82% vs 47%, p <0.001). The difference was driven by lower rates of device malpositioning (9% vs 33%) and aortic regurgitation (AR) ≥ moderate (4% vs 31%) and translated into higher clinical efficacy at 30 days in patients treated with newer as compared with early generation THV (72% vs 56%, p = 0.041). Both THV under- and oversizing were associated with an increased risk of THV malpositioning. In conclusion, TAVI is a feasible treatment strategy in selected high-risk patients with NAVR but is associated with a considerable risk of THV malpositioning and residual AR. Although newer-generation THV are associated with better outcomes, novel devices for the treatment of NAVR are warranted.

AB - Patients with pure native aortic valve regurgitation (NAVR) and increased surgical risk are often denied surgery. This retrospective study aimed to evaluate the "off-label" use of transcatheter heart valves (THV) for the treatment of NAVR. A total of 254 high surgical risk patients with NAVR (age 74 ± 12 years, Society of Thoracic Surgeons risk score 6.6 ± 6.2%) underwent transcatheter aortic valve implantation (TAVI) with early generation (43%) or newer generation (57%) devices at 46 different sites. Device success was significantly higher in patients treated with newer as compared with early generation THV (82% vs 47%, p <0.001). The difference was driven by lower rates of device malpositioning (9% vs 33%) and aortic regurgitation (AR) ≥ moderate (4% vs 31%) and translated into higher clinical efficacy at 30 days in patients treated with newer as compared with early generation THV (72% vs 56%, p = 0.041). Both THV under- and oversizing were associated with an increased risk of THV malpositioning. In conclusion, TAVI is a feasible treatment strategy in selected high-risk patients with NAVR but is associated with a considerable risk of THV malpositioning and residual AR. Although newer-generation THV are associated with better outcomes, novel devices for the treatment of NAVR are warranted.

U2 - 10.1016/j.amjcard.2018.05.044

DO - 10.1016/j.amjcard.2018.05.044

M3 - Journal article

C2 - 30072124

VL - 122

SP - 1028

EP - 1035

JO - Am. J. Cardiol.

JF - Am. J. Cardiol.

SN - 0002-9149

IS - 6

ER -

ID: 218179668